peptidoglycan recognition protein 3Genealiases: PGLYRPIalpha · PGRP-Ialpha · PGRPIA
Q-omics provides the consensus-scored PGLYRP3 profile across patient tissues and cancer cell-line models. PGLYRP3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PGLYRP3 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, PGLYRP3 RNA expression shows 10,152 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BRCA, LUSC, and ESCA as cancer lineages where PGLYRP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGLYRP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGLYRP3 survival associations across molecular data types. PGLYRP3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGLYRP3 RNA expression–survival associations across cancer types. High PGLYRP3 expression shows unfavorable associations in BRCA, KIRC, MESO, LIHC, UCEC and SKCM. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for PGLYRP3 RNA expression.
This table summarizes PGLYRP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PGLYRP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGLYRP3 shows higher tumor expression in LUSC, COAD, LUAD, BLCA, UCEC and BRCA. The LUSC box plot shows higher PGLYRP3 RNA expression in tumor versus normal tissue (log2 FC = +4.535, t-test p < 0.001).
This table shows molecular features associated with PGLYRP3 in patient tissues and cancer cell lines. In patient samples, PGLYRP3 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, PGLYRP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
